On November 5, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti–PD-(L)1 antibody. Amivantamab and hyaluronidase-lpuj is not indicated for patients with oropharyngeal squamous cell carcinoma (OPSCC) that is associated with human papillomavirus (HPV). 

The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has named Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, as the recipient of the 2026 Basser Global Prize.

NYU Langone Health announced the appointment of Vivek Subbiah, MD, as Director of the Early Phase Drug Development Program and the Rare Cancer Program at NYU Langone’s Perlmutter Cancer Center, effective November 1. He will also serve as Professor in the Department of Medicine’s Division of Hematology and Medical Oncology at NYU Grossman School of Medicine.

In the phase III HERON-Lung01 trial, ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy and showed a manageable safety profile in patients with EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to Xu et al. The findings, which were presented during the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract LBA72) and simultaneously published in The Lancet, were interpreted by the investigators as supporting the novel HER3-directed antibody-drug conjugate as a potential standard-of-care option in this setting.